Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma

• Andliena Tahiri,

  Affiliations Department of Clinical Molecular Biology and Laboratory Sciences, Akershus University Hospital, Lørenskog, Norway, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

  ⨯
• Kathrine Røe,

  Affiliations Department of Clinical Molecular Biology and Laboratory Sciences, Akershus University Hospital, Lørenskog, Norway, Department of Oncology, Akershus University Hospital, Lørenskog, Norway

  ⨯
• Anne H. Ree,

  Affiliations Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Department of Oncology, Akershus University Hospital, Lørenskog, Norway

  ⨯
• Rik de Wijn,

  Affiliation PamGene International B.V., ‘s- Hertogenbosch, The Netherlands

  ⨯
• Karianne Risberg,

  Affiliation Department of Oncology, Akershus University Hospital, Lørenskog, Norway

  ⨯
• Christian Busch,

  Affiliation Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway

  ⨯
• Per E. Lønning,

  Affiliations Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway, Department of Oncology, Haukeland University Hospital, Bergen, Norway

  ⨯
• Vessela Kristensen,

  Affiliations Department of Clinical Molecular Biology and Laboratory Sciences, Akershus University Hospital, Lørenskog, Norway, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

  ⨯
• Jürgen Geisler

  * E-mail: juergen.geisler@medisin.uio.no

  Affiliations Department of Clinical Molecular Biology and Laboratory Sciences, Akershus University Hospital, Lørenskog, Norway, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Department of Oncology, Akershus University Hospital, Lørenskog, Norway

  ⨯